GE HealthCare has gotten torched over the last six months - since January 2026, its stock price has dropped 22.7% to $64.05 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.
Is now the time to buy GE HealthCare, or should you be careful about including it in your portfolio? Dive into our full research report to see our analyst team’s opinion, it’s free.
Why Is GE HealthCare Not Exciting?
Even though the stock has become cheaper, we’re cautious about GE HealthCare. Here are three reasons why there are better opportunities than GEHC, plus one stock we’d rather own.
1. Long-Term Revenue Growth Disappoints
A company’s long-term performance is an indicator of its overall quality. Any business can put up a good quarter or two, but many enduring ones grow for years. Over the last four years, GE HealthCare grew its sales at a mediocre 4.4% compounded annual growth rate. This was below our standard for the healthcare sector.
2. Slow Organic Growth Suggests Waning Demand In Core Business
We can better understand Medical Devices & Supplies - Imaging, Diagnostics companies by analyzing their organic revenue. This metric gives visibility into GE HealthCare’s core business because it excludes one-time events such as mergers, acquisitions, and divestitures along with foreign currency fluctuations - non-fundamental factors that can manipulate the income statement.
Over the last two years, GE HealthCare’s organic revenue averaged 3% year-on-year growth. This performance slightly lagged the sector and suggests it may need to improve its products, pricing, or go-to-market strategy, which can add an extra layer of complexity to its operations. 
3. Free Cash Flow Margin Stuck in Neutral
If you’ve followed StockStory for a while, you know we emphasize free cash flow. Why, you ask? We believe that in the end, cash is king, and you can’t use accounting profits to pay the bills.
As you can see below, GE HealthCare’s margin was unchanged over the last five years, showing it couldn’t improve. Its free cash flow margin for the trailing 12 months was 7.2%.
Final Judgment
GE HealthCare isn’t a terrible business, but it doesn’t pass our quality test. After the recent drawdown, the stock trades at 13.1× forward P/E (or $64.05 per share). This valuation multiple is fair, but we don’t have much faith in the company. We’re pretty confident there are superior stocks to buy right now. We’d recommend looking at one of our all-time favorite software stocks.
Stocks We Would Buy Instead of GE HealthCare
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.
